

D4
cont

15. (Twice amended) The method of claims 7 or 9 or 10, wherein said compound is incorporated with a pharmaceutically acceptable carrier and injected into said mammal.

REMARKS

Claims 4-10, 12-19, 22 and 23 were pending in this Application at the time of the Final Rejection. Claims 7, 9-10, and 23 stand allowed by the Examiner in the May 15 Official Action. The remaining claims were finally rejected in the same Official Action. Claims 4-6, 8, 12, 16-19 and 22 are cancelled from the application without prejudice in this Reply leaving only allowed claims 7, 9-10 and 23 and amended claims 13-15 remaining in this case. Claims 13-15 have been amended to depend only upon allowed claims and, therefore, are also allowable. These claim amendments place the application in a condition for immediate allowance.

No new matter has been added to the application by way of these claim amendments. A marked up copy of each amended claim is attached as Appendix A to this Reply. A clean copy of all pending application claims is attached as Appendix B to this Reply.


In view of these claim amendments, Applicants ask the Examiner to withdraw his final rejection and allow all pending application claims.

Respectfully submitted,

**McDonnell Boehnen
Hulbert & Berghoff**

Dated: October 28, 2002

By:


A. Blair Hughes
Reg. No. 32,901
312-913-2123

Appendix A
Marked Up Claims Pursuant To 37 CFR 1.121

13. (Twice amended) The method of claims [5 or 6 or 8]7 or 9 or 10[or 12], wherein said compound is incorporated with inert carriers into a tablet and administered orally.

14. (Twice amended) The method of claims [5 or 6 or 8]7 or 9 or 10[or 12], wherein said compound is incorporated with a propellant and a solvent and administered by inhalation of mist.

15. (Twice amended) The method of claims [5 or 6 or 8]7 or 9 or 10[or 12], wherein said compound is incorporated with a pharmaceutically acceptable carrier and injected into said mammal.